

Date of Approval: December 22, 2023

# FREEDOM OF INFORMATION SUMMARY

## ORIGINAL ABBREVIATED NEW ANIMAL DRUG APPLICATION

ANADA 200-765

EnroPro™ 100

(enrofloxacin)

Injectable Solution

Beef cattle, non-lactating dairy cattle, and swine

**Cattle – Single-Dose Therapy:** EnroPro™ 100 is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and *Mycoplasma bovis* in beef and non-lactating dairy cattle; and for the control of BRD in beef and non-lactating dairy at high risk of developing BRD associated with *M. haemolytica*, *P. multocida*, *H. somni* and *M. bovis*.

**Cattle – Multiple-Day Therapy:** EnroPro™ 100 is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida* and *Histophilus somni* in beef and non-lactating dairy cattle.

**Swine:** EnroPro™ 100 is indicated for the treatment and control of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Haemophilus parasuis*, *Streptococcus suis*, *Bordetella bronchiseptica* and *Mycoplasma hyopneumoniae*. EnroPro 100™ is indicated for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with *Escherichia coli* has been diagnosed.

Sponsored by:

Cronus Pharma Specialities India Private Ltd.

Table of Contents

|                              |   |
|------------------------------|---|
| I. GENERAL INFORMATION ..... | 3 |
| II. BIOEQUIVALENCE.....      | 5 |
| III. HUMAN FOOD SAFETY ..... | 5 |
| IV. USER SAFETY .....        | 6 |
| V. AGENCY CONCLUSIONS.....   | 6 |

**I. GENERAL INFORMATION**

**A. File Number**

ANADA 200-765

**B. Sponsor**

Cronus Pharma Specialities India Private Ltd.,  
Sy No-99/1, M/s GMR Hyderabad Aviation SEZ Ltd.,  
Mamidipalli Village, Shamshabad Mandal,  
Ranga Reddy, Hyderabad, Telangana, 501218, India

Drug Labeler Code: 069043

**C. Proprietary Name**

EnroPro™ 100

**D. Drug Product Established Name**

enrofloxacin

**E. Pharmacological Category**

Antimicrobial

**F. Dosage Form**

Injectable solution

**G. Amount of Active Ingredient**

100 mg/mL

**H. How Supplied**

100 mL, 250 mL, and 500 mL vials

**I. Dispensing Status**

Prescription (Rx)

**J. Dosage Regimen**

EnroPro™ 100 may be administered as a single dose for one day for treatment and control of BRD (cattle), for treatment and control of SRD or for control of colibacillosis (swine), or for multiple days for BRD treatment (cattle). Selection of the appropriate dose and duration of therapy for BRD treatment in cattle should be based on an assessment of the severity of the disease, pathogen susceptibility and clinical response.

**Cattle:**

**Single-Dose Therapy (BRD Treatment):** Administer, by subcutaneous injection, a single dose of 7.5-12.5 mg/kg of body weight (3.4-5.7 mL/100 lb).

**Multiple-Day Therapy (BRD Treatment):** Administer daily, a subcutaneous dose of 2.5-5 mg/kg of body weight (1.1-2.3 mL/100 lb). Treatment should be repeated at 24-hour intervals for three days. Additional treatments may be given on Days 4 and 5 to animals that have shown clinical improvement but not total recovery.

**Single-Dose Therapy (BRD Control):** Administer, by subcutaneous injection, a single dose of 7.5 mg/kg of body weight (3.4 mL/100 lb).

**Swine:**

Administer, either by intramuscular or subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight (3.4 mL/100 lb). Administered dose volume should not exceed 5 mL per injection site.

For the control of colibacillosis, administration should be initiated within the first 60 days post-weaning when clinical signs are present in at least 2% of the animals in the group. If no improvement is noted within 48 hours, the diagnosis should be reevaluated.

**K. Route of Administration**

Beef cattle and non-lactating dairy cattle: subcutaneous injection

Swine: intramuscular or subcutaneous injection

**L. Species/Classes**

Beef cattle, non-lactating dairy cattle, and swine

**M. Indications**

**Cattle – Single-Dose Therapy:** EnroPro™ 100 is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and *Mycoplasma bovis* in beef and non-lactating dairy cattle; and for the control of BRD in beef and non-lactating dairy cattle at high risk of developing BRD associated with *M. haemolytica*, *P. multocida*, *H. somni* and *M. bovis*.

**Cattle – Multiple-Day Therapy:** EnroPro™ 100 is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida* and *Histophilus somni* in beef and non-lactating dairy cattle.

**Swine:** EnroPro™ 100 is indicated for the treatment and control of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Haemophilus parasuis*, *Streptococcus suis*, *Bordetella bronchiseptica* and *Mycoplasma hyopneumoniae*. EnroPro™ 100 is indicated for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with *Escherichia coli* has been diagnosed.

## **N. Reference Listed New Animal Drug (RLNAD)**

Baytril® 100; enrofloxacin; NADA 141-068; Elanco US Inc.

## **II. BIOEQUIVALENCE**

The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Generic Animal Drug and Patent Term Restoration Act (GADPTRA) of 1988, allows for an abbreviated new animal drug application (ANADA) to be submitted for a generic version of an approved new animal drug (RLNAD). The ANADA sponsor is required to show that the generic product is bioequivalent to the RLNAD, which has been shown to be safe and effective. Effectiveness, target animal safety and human food safety data (other than tissue residue data) are not required for approval of an ANADA. If bioequivalence is demonstrated through a clinical endpoint study in a food-producing animal, then a tissue residue study to establish the withdrawal period for the generic product is also required. For certain dosage forms, the agency will grant a waiver from the requirement to perform *in vivo* bioequivalence studies (biowaiver) (55 FR 24645, June 18, 1990; Fifth GADPTRA Policy Letter; Bioequivalence Guideline, October 9, 2002).

Based on the formulation characteristics of the generic product, Cronus Pharma Specialities Private Ltd., was granted a biowaiver for the generic product EnroPro™ 100 (enrofloxacin) injectable solution. The generic drug product is an injectable solution, contains the same active ingredient in the same concentration and dosage form as the RLNAD, and contains no inactive ingredients that may significantly affect the bioavailability of the active ingredient. The RLNAD is Baytril® 100 (enrofloxacin) injectable solution, sponsored by Elanco US Inc., under NADA 141-068, and was approved for use in cattle on July 24, 1998, and in swine on March 14, 2008.

## **III. HUMAN FOOD SAFETY**

The tolerances for residues and withdrawal periods established for the RLNAD apply to the generic product. The following are assigned to this product for beef cattle, non-lactating dairy cattle and swine:

### **A. Acceptable Daily Intake and Tolerances for Residues**

The acceptable daily intake (ADI) for total residues of enrofloxacin is 3 µg/kg of body weight per day. The tolerances established for the RLNAD apply to the generic product. A tolerance of 0.1 ppm is established for desethylene ciprofloxacin (the marker residue) in cattle liver (the target tissue), and a tolerance of 0.5 ppm is established for enrofloxacin (the marker residue) in swine liver (the target tissue), under 21 CFR 556.226.

### **B. Withdrawal Period**

Because a biowaiver was granted, the withdrawal periods are those previously assigned to the RLNAD product. A withdrawal period of 28 days has been established for enrofloxacin in beef and non-lactating dairy cattle. A withdrawal period of 5 days has been established for enrofloxacin in swine.

### C. Analytical Method for Residues

The validated analytical method for analysis of residues of enrofloxacin is on file at the Center for Veterinary Medicine, 7500 Standish Place, Rockville, MD 20855. To obtain a copy of the analytical method, please submit a Freedom of Information request to: <https://www.accessdata.fda.gov/scripts/foi/FOIRequest/requestinfo.cfm>.

### IV. USER SAFETY

The product labeling contains the following information regarding safety to humans handling, administering, or exposed to EnroPro™ 100:

#### **Human Warnings:**

**Not for use in humans. Keep out of reach of children.** Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposures. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Cronus Pharma LLC at 1-844-227-6687 or 1-844-2-CRONUS. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at [www.fda.gov/reportanimalae](http://www.fda.gov/reportanimalae).

### V. AGENCY CONCLUSIONS

The data submitted in support of this ANADA satisfy the requirements of section 512(c)(2) of the FD&C Act. The data demonstrate that EnroPro™ 100, when used according to the label, is safe and effective for the conditions of use in the General Information Section above.

Additionally, data demonstrate that residues in food products derived from beef cattle, non-lactating dairy cattle and swine treated with EnroPro™ 100 will not represent a public health concern when the product is used according to the label.